Search results for "EGF"

showing 10 items of 331 documents

Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis

2014

The EGFR/PI3K/PTEN/Akt/mTORC pathway plays prominent roles in malignant transformation, prevention of apoptosis, drug resistance, cancer initiating cells (CICs) and metastasis. The expression of this pathway is frequently altered in breast and other cancers due to mutations at or aberrant expression of: HER2, EGFR1, PIK3CA, and PTEN as well as other oncogenes and tumor suppressor genes. miRs and epigenetic mechanisms of gene regulation are also important events which regulate this pathway. In some breast cancer cases, mutations at certain components of this pathway (e.g., PIK3CA) are associated with a better prognosis than breast cancers lacking these mutations. The expression of this pathw…

MaleOncologyCancer Researchmedicine.medical_treatmentTargeted therapyMetastasisTargeted therapyBreast cancerNeoplasmsNeoplasm MetastasisCancer stem cellsMedicine (all)Neoplasm ProteinsNeoplasm MetastasiGene Expression Regulation NeoplasticCell Transformation NeoplasticMolecular MedicineFemaleHormonal therapyHumanSignal Transductionmedicine.medical_specialtyEGFRBiologyNeoplasm ProteinBreast cancerGeneticCancer stem cellInternal medicineHER2GeneticsmedicineAnimalsHumansPTENMolecular BiologyProtein kinase BPI3K/AKT/mTOR pathwayCell ProliferationAnimalCancer stem cellTherapy resistanceCancermedicine.diseaseERDrug Resistance NeoplasmBreast cancer; Cancer stem cells; EGFR; ER; HER2; Hormonal therapy; Targeted therapy; Therapy resistancebiology.proteinCancer researchNeoplasm
researchProduct

Functional FLT1 genetic variation is a prognostic factor for recurrence in stage I-III non-small cell lung cancer

2015

Background: We propose that single-nucleotide polymorphisms (SNPs) in genes of the vascular endothelial growth factor pathway of angiogenesis will associate with survival in non-small-cell lung cancer (NSCLC) patients. Methods: Fifty-three SNPs in vascular endothelial growth factor-pathway genes were genotyped in 150 European stage I-III NSCLC patients and tested for associations with patient survival. Replication was performed in an independent cohort of 142 European stage I-III patients. Reporter gene assays were used to assess the effects of SNPs on transcriptional activity. Results: In the initial cohort, five SNPs associated (q < 0.05) with relapse-free survival (RFS). The minor allele…

MaleOncologyLung NeoplasmsAngiogenesisBioinformaticsmedicine.disease_causeCohort Studies0302 clinical medicineNon-small cell lung cancerVEGF pathwayCarcinoma Non-Small-Cell LungFLT1Aged 80 and over0303 health sciencesHazard ratioMiddle AgedPrognosis3. Good healthOncology030220 oncology & carcinogenesisFemaleKRASSNPsAdultPulmonary and Respiratory Medicinemedicine.medical_specialtySingle-nucleotide polymorphismPolymorphism Single NucleotideDisease-Free SurvivalArticle03 medical and health sciencesInternal medicineBiomarkers TumormedicineHumansNon–small cell lung cancerSNPLung cancerSurvival analysisAgedNeoplasm Staging030304 developmental biologyVascular Endothelial Growth Factor Receptor-1business.industryGenetic VariationMICROBIOLOGIAmedicine.diseaseSurvival AnalysisMinor allele frequencyNeoplasm Recurrence LocalbusinessEnhancer
researchProduct

Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cance…

2019

Abstract Background The aim of the study was to investigate the feasibility of Epidermal Growth Factor Receptor (EGFR) measurement in bladder washings of patients affected by non–muscle-invasive bladder cancer (NMIBC) and its prognostic role in identifying risk subgroups and predicting disease recurrence and progression. Patients and Methods Patients with NMIBC treated with transurethral resection of bladder tumor (TURBT) from 2012 to 2015 were enrolled. Samples of bladder washings were collected and stored at −80°C until RNA extraction. The cDNA obtained from RNA was used to perform a gene expression analysis by a real time polymerase chain reaction. Results An adequate cellular pellet was…

MaleOncologymedicine.medical_specialtyUrology030232 urology & nephrologyCystectomy03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicineAdjuvant therapyHumansMedicineEpidermal growth factor receptorAgedBladder cancerBladder washingbiologybusiness.industryHazard ratioCancerBiomarkerPrognosismedicine.diseaseConfidence intervalEpidermal Growth Factor Receptor (EGFR)Up-RegulationErbB ReceptorsGene Expression Regulation NeoplasticAdministration IntravesicalTreatment OutcomeUrinary Bladder NeoplasmsOncologyNon-Muscle Invasive Bladder Cancer (NMIBC)Chemotherapy Adjuvant030220 oncology & carcinogenesisMolecular classificationDisease Progressionbiology.proteinFeasibility StudiesBiomarker (medicine)Femalebusiness
researchProduct

Condensed Versus Standard Schedule of High-Dose Cytarabine Consolidation Therapy with Pegfilgrastim Growth Factor Support in Acute Myeloid Leukemia

2017

Abstract Background: The concept of intensive post-remission chemotherapy in acute myeloid leukemia (AML) is based on the observation that despite achievement of a first complete remission (CR) after intensive induction therapy virtually all patients relapse in the absence of further treatment. Moreover, randomized studies showed that intensive post-remission consolidation chemotherapy was superior to prolonged low-dose maintenance therapy in younger patients. With regard to consolidation therapy, the landmark study conducted by the Cancer and Leukemia Group B established the current standard for patients aged 60 years and younger with high-dose cytarabine (HDAC) 3g/m² bidaily on days days …

MaleOncologymedicine.medical_treatmentHematopoietic stem cell transplantationGastroenterologyBiochemistryPolyethylene Glycols0302 clinical medicineMaintenance therapyAntineoplastic Combined Chemotherapy ProtocolsMedicineCytarabineMyeloid leukemiaHematologyMiddle AgedChemotherapy regimen3. Good healthSurvival RateLeukemia Myeloid AcuteLeukemiaOncology030220 oncology & carcinogenesisOriginal ArticleFemalePegfilgrastimmedicine.drugAdultmedicine.medical_specialtyAdolescentFilgrastimImmunologyPlatelet TransfusionFilgrastimDisease-Free Survival03 medical and health sciencesInternal medicineHumansIdarubicinSurvival rateChemotherapybusiness.industryDaunorubicinConsolidation ChemotherapyCell BiologyLength of Staymedicine.diseaseSurgeryConsolidation ChemotherapyTransplantationPlatelet transfusionCytarabinebusiness030215 immunologyBlood
researchProduct

Non-viral VEGF(165) gene therapy--magnetofection of acoustically active magnetic lipospheres ('magnetobubbles') increases tissue survival in an overs…

2008

Abstract Adenoviral transduction of the VEGF gene in an oversized skin flap increases flap survival and perfusion. In this study, we investigated the potential of magnetofection of magnetic lipospheres containing VEGF165-cDNA on survival and perfusion of ischemic skin flaps and evaluated the method with respect to the significance of applied magnetic field and ultrasound. We prepared perfluoropropane-filled magnetic lipospheres (‘magnetobubbles’) from Tween60-coated magnetic nanoparticles, Metafectene, soybean-oil and cDNA and studied the effect in an oversized random-pattern-flap model in the rats (n= 46). VEGF-cDNA-magnetobubbles were administered under a magnetic field with simultaneousl…

MalePathologymedicine.medical_specialtyNecrosismagneticAngiogenesisGenetic enhancementDermatologic Surgical ProceduresEnzyme-Linked Immunosorbent AssayTransfectionSurgical FlapsRats Sprague-DawleyMagneticsangiogenesismagnetobubblesmedicineAnimalsUltrasonicsSkinbusiness.industryVascular Endothelial Growth FactorsMusclesUltrasoundGraft SurvivalCell BiologyTransfectionGenetic TherapySkin TransplantationArticlesequipment and suppliesLipidsVEGFgene therapyMicrospheresRatsMicrovesselsModels AnimalMagnetofectionMolecular MedicineMagnetic nanoparticleslipospheresmedicine.symptombusinessPerfusionhuman activitiesmagnetofectionJournal of cellular and molecular medicine
researchProduct

How Have Intravitreal Anti-VEGF and Dexamethasone Implant Been Used in Italy? A Multiregional, Population-Based Study in the Years 2010–2016

2020

Purpose. To describe intravitreal anti-VEGF drug and dexamethasone use in four Italian regions. Methods. Four regional claims databases were used to measure drug prevalence, compare dosing intervals to those recommended in the summary of product characteristics (SPC), and identify switchers. Bilateral treatment and diabetic macular edema (DME) coding algorithms were validated, linking claims with a sample of prospectively collected ophthalmological data. Results. Overall, 41,836 patients received ≥1 study drug in 2010–2016 (4.8 per 10,000 persons). In 2016, anti-VEGF drug use ranged from 0.8 (Basilicata) to 5.7 (Lombardy) per 10,000 persons while intravitreal dexamethasone use ranged from 0…

MaleVascular Endothelial Growth Factor A0301 basic medicineintravitrealAngiogenesis Inhibitorsalgorithm.0302 clinical medicineMedicineSummary of Product Characteristicsmedia_commonAged 80 and overDrug ImplantsvalidationLaser CoagulationRGeneral MedicineMiddle AgedItalyanti-VEGF030220 oncology & carcinogenesisMedicineFemaleclinical dataoriginal articleResearch Articlemedicine.drugDrugmedicine.medical_specialtyArticle Subjectmedia_common.quotation_subjectMEDLINEdexamethasonePharmacyMacular EdemaGeneral Biochemistry Genetics and Molecular BiologyInsurance Claim Review03 medical and health sciencesRanibizumabInternal medicineHumansDosingDexamethasoneAgedDiabetic RetinopathyGeneral Immunology and MicrobiologySettore MED/30 - Malattie Apparato Visivobusiness.industryclaims database030104 developmental biologydrug utilisationMacular Edema; Ranibizumab; Laser CoagulationImplantRanibizumabbusinessBioMed Research International
researchProduct

Association of neovascular age-related macular degeneration with month and season of birth in Italy

2016

In order to investigate the influence of season and month of birth on the risk of neovascular age-related macular degeneration (n-AMD) in Italy, we evaluated the month birth and sex of all patients, recorded in the anti-vascular endothelial growth factor (VEGF) monitoring registry of the Italian Medicines Agency, born between 1925-1944, who received intravitreal anti-VEGF injections for n-AMD between January 1, 2013 and July 29, 2015. The numbers of all births in Italy in the same years, extracted from the Italian National Institute of Statistics, were used to calculate the expected number of n-AMD cases. Overall, 45,845 patients (19,207 men, 26,638 women) received intravitreal anti-VEGF fo…

MaleVascular Endothelial Growth Factor AAginggenetic structuresMonth of birthVEGF receptorsneovascular AMDAngiogenesis InhibitorsAptamersMacular Degeneration0302 clinical medicineSeason of birthReceptors80 and overMedicineRegistriesAged 80 and overNeovascularization PathologicbiologyVascular Endothelial Growth FactorIncidenceIncidence (epidemiology)Aptamers NucleotideBevacizumabTreatment OutcomeItalyanti-VEGFFemaleSeasonsNucleotideNeovascular age-related macular degenerationResearch Papermedicine.drugAnti-VEGF; Month of birth; Neovascular age-related macular degeneration; Neovascular AMD; Season of birth; Aged; Aged 80 and over; Angiogenesis Inhibitors; Aptamers Nucleotide; Bevacizumab; Female; Humans; Incidence; Italy; Macular Degeneration; Male; Neovascularization Pathologic; Ranibizumab; Receptors Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Registries; Treatment Outcome; Vascular Endothelial Growth Factor A; Seasons; Aging; Cell BiologySeason of birthBevacizumabRecombinant Fusion ProteinsNeovascular AMDneovascular age-related macular degeneration03 medical and health sciencesRanibizumabAge relatedHumansNeovascularizationAgedPathologicseason of birthbusiness.industrymonth of birthAnti-VEGFCell BiologyMacular degenerationmedicine.diseaseeye diseasesanti-VEGF; month of birth; neovascular AMD; neovascular age-related macular degeneration; season of birthReceptors Vascular Endothelial Growth Factor030221 ophthalmology & optometrybiology.proteinsense organsRanibizumabbusinessMonth of birth030217 neurology & neurosurgeryDemographyAging
researchProduct

High concentration of C-type natriuretic peptide promotes VEGF-dependent vasculogenesis in the remodeled region of infarcted swine heart with preserv…

2013

Vasculogenesis is a hallmark of myocardial restoration. Post-ischemic late remodeling is associated with pathology and function worsening. At the same time, neo-vasculogenesis helps function improving and requires the release of vascular endothelial growth factor type A (VEGF-A). The vasculogenic role of C-type natriuretic peptide (CNP), a cardiac paracrine hormone, is unknown in infarcted hearts with preserved left ventricular (LV) ejection fraction (EF). We explored whether myocardial VEGF-dependent vasculogenesis is affected by CNP.To this end, infarcted swine hearts were investigated by magnetic resonance imaging (MRI), histological and molecular assays. At the fourth week, MRI showed t…

MaleVascular Endothelial Growth Factor AC-type natriuretic peptide Ischemic remodeling Myocardial infarction Paracrinicity Vasculogenesis VEGFmedicine.medical_specialtymedicine.drug_classSwineMyocardial InfarctionNeovascularization PhysiologicVentricular Function Leftchemistry.chemical_compoundVasculogenesisParacrinicityInternal medicineVasculogenesismedicineNatriuretic peptideAnimalsMyocardial infarctionVentricular remodelingEjection fractionmedicine.diagnostic_testVentricular Remodelingbusiness.industryMagnetic resonance imagingNatriuretic Peptide C-Typemedicine.diseaseVEGFVascular endothelial growth factorVascular endothelial growth factor AchemistryIschemic remodelingCardiologyCardiology and Cardiovascular MedicinebusinessC-type natriuretic peptideInternational journal of cardiology
researchProduct

Association Between Single Nucleotide Polymorphisms in the Cyclooxygenase-2, Tumor Necrosis Factor-α, and Vascular Endothelial Growth Factor-A Genes,…

2011

Cyclooxygenase-2 (COX-2), vascular endothelial growth factor-A (VEGF-A), and tumor necrosis factor-α (TNF-α) are mediators of inflammation and angiogenesis; all of them are produced in liver cirrhosis (LC) and in hepatocellular carcinoma (HCC). It was proposed that there is an association between single nucleotide polymorphisms (SNPs) and HCC. These allelic variants influence the transcriptional activity of these genes, and therefore the proteins levels. The VEGF-A pathway is a potential therapeutic target in HCC, and several antiangiogenic agents have entered clinical trials in HCC. We evaluated the frequency of SNPs of COX-2, TNF-α, and VEGF-A genes in patients with HCC versus LC patients…

MaleVascular Endothelial Growth Factor AHeterozygoteCarcinoma HepatocellularCirrhosisAngiogenesisSingle-nucleotide polymorphismBiologyPolymorphism Single NucleotideBiochemistryCOX-2 TNFa VEGF Hepatocellular Carcinoma SNPsGeneticsmedicineHumansneoplasmsMolecular BiologyTumor Necrosis Factor-alphaHomozygoteLiver Neoplasmsnucleotide polymorphisms cyclooxygenase-2 tumor necrosis factor-α vascular endothelial growth factor-A geneshepatocellular carcinoma.Heterozygote advantagemedicine.diseasedigestive system diseasesVascular endothelial growth factor ACyclooxygenase 2Hepatocellular carcinomaImmunologyCancer researchMolecular MedicineFemaleTumor necrosis factor alphaRestriction fragment length polymorphismBiotechnologyOMICS: A Journal of Integrative Biology
researchProduct

Engineered microenvironments for synergistic VEGF - Integrin signalling during vascularization

2017

We have engineered polymer-based microenvironments that promote vasculogenesis both in vitro and in vivo through synergistic integrin-growth factor receptor signalling. Poly(ethyl acrylate) (PEA) triggers spontaneous organization of fibronectin (FN) into nanonetworks which provide availability of critical binding domains. Importantly, the growth factor binding (FNIII12-14) and integrin binding (FNIII9-10) regions are simultaneously available on FN fibrils assembled on PEA. This material platform promotes synergistic integrin/VEGF signalling which is highly effective for vascularization events in vitro with low concentrations of VEGF. VEGF specifically binds to FN fibrils on PEA compared to …

MaleVascular Endothelial Growth Factor AIntegrinsBiophysicsNeovascularization PhysiologicBioengineeringpoly(ethyl acrylate)ArticleBiomaterialsHuman Umbilical Vein Endothelial CellsImage Processing Computer-AssistedAnimalsHumansPhosphorylationExtracellular Signal-Regulated MAP KinasesFibronectinTissue EngineeringPhospholipase C gammaProtein assemblyVascularizationVEGFFibronectinsMice Inbred C57BLCellular MicroenvironmentMechanics of MaterialsFocal Adhesion Protein-Tyrosine KinasesFISICA APLICADAMutationCeramics and CompositesINGENIERIA ELECTRICAGrowth factorsProtein BindingSignal Transduction
researchProduct